🚀 Fresh from the Host-Pathogen Interactions lab at iMed.ULisboa, a new paper titled “Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of Mycobacterium tuberculosis” has just been #Published. 📚Increasing evidence supports the repositioning of beta-lactams for tuberculosis (TB) therapy, but further research on their interaction with conventional anti-TB agents is still warranted. This study aimed to identify synergies between beta-lactams and anti-TB drugs ethambutol and isoniazid by assessing antimicrobial effects, intracellular activity, and immune responses. Ultimately, it demonstrated that pairing beta-lactams with ethambutol significantly improves their efficacy against Mycobacterium tuberculosis. (Adapted from the Abstract.) 💥 Congratulations to the authors Francisco Olivença, David Pires, Cátia Silveiro, Bianca Gama, Frederico Holtreman, Elsa Anes, Maria João Catalão! 🔎 You can read the full article here: https://lnkd.in/gJKWZNYG #MycobacteriumTuberculosis, #AntimicrobialResistance, #Carbapenems, #AntibioticSynergy